Regulatory pharmacology and toxicology studies, in accordance with standard protocols, have been completed by Central Drugs Research Laboratory (CDRI) , Govt of India on the standardized Brahmi extract contained in MemoryPlus (product of CDRI).

The LD50 of the standardized Brahmi extract was found to be more than 3000 mg/kg p.o. in two rodent species. In the regulatory pharmacology studies the Brahmi extract produced no harmful effects on gross behavior and innate and motivated responses or any other bodily system at doses 25 times higher than the effective dose. The regulatory sub-acute toxicity of the standardized Brahmi extract was carried out, by oral route, in rodent and non-human primate specimens and was found to be safe.